A formulation of Curcumin (Theracurmin, 90–180 mg/day, for 18 months), having p300/CBP HAT inhibitory activity, is currently in phase II clinical trials to test its efficacy to improve cognitive function and reduce Aβ-deposition in AD patients (ClinicalTrials.gov Identifier: NCT01383161, accessed on 29 October, 2024) [251,262]. This evidence concerns the gene EP300 and Alzheimer disease.